Sponsors / CORT
CORT

Corcept Therapeutics

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
12Trials in this database
22Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeNCT03604198Corcept TherapeuticsPhase 2Active not recruiting2026-12Estimated
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeNCT03697109Corcept TherapeuticsPhase 3Completed2024-04-08Actual
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812Corcept TherapeuticsPhase 2Completed2021-03-16Actual
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsNCT03818256Corcept TherapeuticsPhase 2Completed2022-06-17Actual
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasNCT04308590Corcept TherapeuticsPhase 3Completed2024-09-19Actual
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT04329949Corcept TherapeuticsPhase 3Terminated2021-08-23Actual
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)NCT04524403Corcept TherapeuticsPhase 2Completed2022-07-29Actual
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerNCT05257408Corcept TherapeuticsPhase 3Active not recruiting2025-03-31Actual
Dazucorilant in Patients With Amyotrophic Lateral SclerosisNCT05407324Corcept TherapeuticsPhase 2Active not recruiting2026-10Estimated
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)NCT06108219Corcept TherapeuticsPhase 2Completed2026-02-13Actual
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Corcept TherapeuticsPhase 2Recruiting2026-08Estimated
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317Corcept TherapeuticsPhase 2Recruiting2027-09Estimated

Latest recorded trial changes

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408 · Corcept Therapeutics

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Progression-free Survival as Assessed by BICR; description: Time from randomization until the time of first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first; timeFrame: Up to 24 months from enrollment of the last patient; measure: Overall survival; description: Time from randomization to death by any cause; timeFrame: Up to 24 months from enrollment of the last patient

+ Updated value

measure: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR); description: PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions.; timeFrame: Up to 20 months; measure: Overall Survival; description: Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates.; timeFrame: Up to 32 months

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317 · Corcept Therapeutics

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Progression-Free Survival (PFS)

+ Updated value

measure: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1); measure: Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1); measure: Progression-Free Survival (PFS) (Part 2)

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324 · Corcept Therapeutics

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.; measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs.

+ Updated value

measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.; measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs; measure: Incidence of treatment-emergent AEs and SAEs; measure: Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug

Check registry source · The saved outcome text may be shortened. Check the source for full wording.